<DOC>
	<DOC>NCT02734615</DOC>
	<brief_summary>To characterize the safety and tolerability, identify recommended doses and regimens for future studies, pharmacokinetics (PK), pharmacodynamics (PD) and anti-tumor activity of LSZ102 as a single agent and in combination with either LEE011 or BYL719 in adult patients with locally advanced or metastatic ER+ breast cancer who have progressed after endocrine therapy.</brief_summary>
	<brief_title>Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast Cancers</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Written informed consent must be obtained prior to any procedures Histologically and/or cytologically confirmed diagnosis of ER+ breast cancer Advanced or metastatic breast cancer Objective evidence of either progression after endocrine therapy for metastatic or locally advanced disease OR recurrence while on, or within 12 months of the end of adjuvant treatment with letrozole or anastrozole Must be able to swallow tablets and capsules Symptomatic CNS metastases Patients whose laboratory values do not meet protocol criteria Clinically significant cardiac disease Impaired gastrointestinal function (GI) or GI disease that may significantly alter the absorption of oral medications Other protocol defined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>LSZ102</keyword>
	<keyword>ER+ breast cancer</keyword>
	<keyword>advanced ER+ breast cancer</keyword>
	<keyword>metastatic ER+ breast cancer</keyword>
	<keyword>SERD</keyword>
	<keyword>SERM</keyword>
	<keyword>fulvestrant</keyword>
	<keyword>tamoxifen</keyword>
	<keyword>aromatase inhibitor</keyword>
	<keyword>ESR1</keyword>
	<keyword>estrogen receptor</keyword>
	<keyword>endocrine therapy</keyword>
</DOC>